Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
JANX

JANX - Janux Therapeutics, Inc. Stock Price, Fair Value and News

$13.56-0.38 (-2.73%)
Market Closed

51/100

JANX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

JANX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

JANX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JANX Price Action

Last 7 days

-2.0%

Last 30 days

3.4%

Last 90 days

-11.4%

Trailing 12 Months

-56.7%

JANX RSI Chart

JANX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JANX Valuation

Market Cap

824.9M

Price/Earnings (Trailing)

-7.26

Price/Sales (Trailing)

18.73

Price/Free Cashflow

-9.91

JANX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

JANX Fundamentals

JANX Revenue

Revenue (TTM)

44.0M

Rev. Growth (Yr)

18.73%

Rev. Growth (Qtr)

-4.42%

JANX Earnings

Earnings (TTM)

-113.6M

Earnings Growth (Yr)

-58.02%

Earnings Growth (Qtr)

-31.39%

JANX Profitability

Return on Equity

-11.88%

Return on Assets

-11.34%

Free Cashflow Yield

-10.1%

JANX Investor Care

Shares Dilution (1Y)

2.92%

Diluted EPS (TTM)

-1.83

JANX Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202535.8M39.2M42.4M44.0M
202417.3M21.9M25.4M29.9M
20236.7M9.6M12.0M14.7M
20223.4M3.3M3.9M4.0M
20210003.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Janux Therapeutics, Inc.

JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
 CEO
 WEBSITEjanuxrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES67

Janux Therapeutics, Inc. Frequently Asked Questions

JANX is the stock ticker symbol of Janux Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Janux Therapeutics, Inc. is 824.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, JANX's PE ratio (Price to Earnings) is -7.26 and Price to Sales (PS) ratio is 18.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JANX PE ratio will change depending on the future growth rate expectations of investors.